Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global COVID-19 Inactivated Vaccine Market Size Growth Rate by Type: 2018 VS 2023 VS 2033
1.2.2 In Clinical Trials
1.2.3 Out-of-Clinical Trials
1.3 Market by Application
1.3.1 Global COVID-19 Inactivated Vaccine Market Growth by Application: 2018 VS 2023 VS 2033
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global COVID-19 Inactivated Vaccine Market Perspective (2018-2033)
2.2 COVID-19 Inactivated Vaccine Growth Trends by Region
2.2.1 Global COVID-19 Inactivated Vaccine Market Size by Region: 2018 VS 2023 VS 2033
2.2.2 COVID-19 Inactivated Vaccine Historic Market Size by Region (2018-2023)
2.2.3 COVID-19 Inactivated Vaccine Forecasted Market Size by Region (2024-2033)
2.3 COVID-19 Inactivated Vaccine Market Dynamics
2.3.1 COVID-19 Inactivated Vaccine Industry Trends
2.3.2 COVID-19 Inactivated Vaccine Market Drivers
2.3.3 COVID-19 Inactivated Vaccine Market Challenges
2.3.4 COVID-19 Inactivated Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top COVID-19 Inactivated Vaccine Players by Revenue
3.1.1 Global Top COVID-19 Inactivated Vaccine Players by Revenue (2018-2023)
3.1.2 Global COVID-19 Inactivated Vaccine Revenue Market Share by Players (2018-2023)
3.2 Global COVID-19 Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by COVID-19 Inactivated Vaccine Revenue
3.4 Global COVID-19 Inactivated Vaccine Market Concentration Ratio
3.4.1 Global COVID-19 Inactivated Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by COVID-19 Inactivated Vaccine Revenue in 2023
3.5 COVID-19 Inactivated Vaccine Key Players Head office and Area Served
3.6 Key Players COVID-19 Inactivated Vaccine Product Solution and Service
3.7 Date of Enter into COVID-19 Inactivated Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 COVID-19 Inactivated Vaccine Breakdown Data by Type
4.1 Global COVID-19 Inactivated Vaccine Historic Market Size by Type (2018-2023)
4.2 Global COVID-19 Inactivated Vaccine Forecasted Market Size by Type (2024-2033)
5 COVID-19 Inactivated Vaccine Breakdown Data by Application
5.1 Global COVID-19 Inactivated Vaccine Historic Market Size by Application (2018-2023)
5.2 Global COVID-19 Inactivated Vaccine Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America COVID-19 Inactivated Vaccine Market Size (2018-2033)
6.2 North America COVID-19 Inactivated Vaccine Market Growth Rate by Country: 2018 VS 2023 VS 2033
6.3 North America COVID-19 Inactivated Vaccine Market Size by Country (2018-2023)
6.4 North America COVID-19 Inactivated Vaccine Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe COVID-19 Inactivated Vaccine Market Size (2018-2033)
7.2 Europe COVID-19 Inactivated Vaccine Market Growth Rate by Country: 2018 VS 2023 VS 2033
7.3 Europe COVID-19 Inactivated Vaccine Market Size by Country (2018-2023)
7.4 Europe COVID-19 Inactivated Vaccine Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific COVID-19 Inactivated Vaccine Market Size (2018-2033)
8.2 Asia-Pacific COVID-19 Inactivated Vaccine Market Growth Rate by Region: 2018 VS 2023 VS 2033
8.3 Asia-Pacific COVID-19 Inactivated Vaccine Market Size by Region (2018-2023)
8.4 Asia-Pacific COVID-19 Inactivated Vaccine Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America COVID-19 Inactivated Vaccine Market Size (2018-2033)
9.2 Latin America COVID-19 Inactivated Vaccine Market Growth Rate by Country: 2018 VS 2023 VS 2033
9.3 Latin America COVID-19 Inactivated Vaccine Market Size by Country (2018-2023)
9.4 Latin America COVID-19 Inactivated Vaccine Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa COVID-19 Inactivated Vaccine Market Size (2018-2033)
10.2 Middle East & Africa COVID-19 Inactivated Vaccine Market Growth Rate by Country: 2018 VS 2023 VS 2033
10.3 Middle East & Africa COVID-19 Inactivated Vaccine Market Size by Country (2018-2023)
10.4 Middle East & Africa COVID-19 Inactivated Vaccine Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Inovio Pharmaceuticals
11.1.1 Inovio Pharmaceuticals Company Detail
11.1.2 Inovio Pharmaceuticals Business Overview
11.1.3 Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Introduction
11.1.4 Inovio Pharmaceuticals Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.1.5 Inovio Pharmaceuticals Recent Development
11.2 Takis Biotech (Evvivax)
11.2.1 Takis Biotech (Evvivax) Company Detail
11.2.2 Takis Biotech (Evvivax) Business Overview
11.2.3 Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Introduction
11.2.4 Takis Biotech (Evvivax) Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.2.5 Takis Biotech (Evvivax) Recent Development
11.3 Zydus Cadila
11.3.1 Zydus Cadila Company Detail
11.3.2 Zydus Cadila Business Overview
11.3.3 Zydus Cadila COVID-19 Inactivated Vaccine Introduction
11.3.4 Zydus Cadila Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.3.5 Zydus Cadila Recent Development
11.4 Codagenix, Inc.
11.4.1 Codagenix, Inc. Company Detail
11.4.2 Codagenix, Inc. Business Overview
11.4.3 Codagenix, Inc. COVID-19 Inactivated Vaccine Introduction
11.4.4 Codagenix, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.4.5 Codagenix, Inc. Recent Development
11.5 GeoVax, Inc.
11.5.1 GeoVax, Inc. Company Detail
11.5.2 GeoVax, Inc. Business Overview
11.5.3 GeoVax, Inc. COVID-19 Inactivated Vaccine Introduction
11.5.4 GeoVax, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.5.5 GeoVax, Inc. Recent Development
11.6 Bravovax
11.6.1 Bravovax Company Detail
11.6.2 Bravovax Business Overview
11.6.3 Bravovax COVID-19 Inactivated Vaccine Introduction
11.6.4 Bravovax Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.6.5 Bravovax Recent Development
11.7 Janssen Pharmaceutical Companies
11.7.1 Janssen Pharmaceutical Companies Company Detail
11.7.2 Janssen Pharmaceutical Companies Business Overview
11.7.3 Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Introduction
11.7.4 Janssen Pharmaceutical Companies Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.7.5 Janssen Pharmaceutical Companies Recent Development
11.8 Altimmune
11.8.1 Altimmune Company Detail
11.8.2 Altimmune Business Overview
11.8.3 Altimmune COVID-19 Inactivated Vaccine Introduction
11.8.4 Altimmune Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.8.5 Altimmune Recent Development
11.9 Vaxart
11.9.1 Vaxart Company Detail
11.9.2 Vaxart Business Overview
11.9.3 Vaxart COVID-19 Inactivated Vaccine Introduction
11.9.4 Vaxart Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.9.5 Vaxart Recent Development
11.10 CanSino Biologics
11.10.1 CanSino Biologics Company Detail
11.10.2 CanSino Biologics Business Overview
11.10.3 CanSino Biologics COVID-19 Inactivated Vaccine Introduction
11.10.4 CanSino Biologics Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.10.5 CanSino Biologics Recent Development
11.11 ExpreS2ion Biotechnologies ApS
11.11.1 ExpreS2ion Biotechnologies ApS Company Detail
11.11.2 ExpreS2ion Biotechnologies ApS Business Overview
11.11.3 ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Introduction
11.11.4 ExpreS2ion Biotechnologies ApS Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.11.5 ExpreS2ion Biotechnologies ApS Recent Development
11.12 Clover Biopharmaceuticals
11.12.1 Clover Biopharmaceuticals Company Detail
11.12.2 Clover Biopharmaceuticals Business Overview
11.12.3 Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Introduction
11.12.4 Clover Biopharmaceuticals Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.12.5 Clover Biopharmaceuticals Recent Development
11.13 GSK
11.13.1 GSK Company Detail
11.13.2 GSK Business Overview
11.13.3 GSK COVID-19 Inactivated Vaccine Introduction
11.13.4 GSK Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.13.5 GSK Recent Development
11.14 Vaxil Bio Ltd.
11.14.1 Vaxil Bio Ltd. Company Detail
11.14.2 Vaxil Bio Ltd. Business Overview
11.14.3 Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Introduction
11.14.4 Vaxil Bio Ltd. Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.14.5 Vaxil Bio Ltd. Recent Development
11.15 Generex
11.15.1 Generex Company Detail
11.15.2 Generex Business Overview
11.15.3 Generex COVID-19 Inactivated Vaccine Introduction
11.15.4 Generex Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.15.5 Generex Recent Development
11.16 Novavax, Inc.
11.16.1 Novavax, Inc. Company Detail
11.16.2 Novavax, Inc. Business Overview
11.16.3 Novavax, Inc. COVID-19 Inactivated Vaccine Introduction
11.16.4 Novavax, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.16.5 Novavax, Inc. Recent Development
11.17 Sanofi Pasteur
11.17.1 Sanofi Pasteur Company Detail
11.17.2 Sanofi Pasteur Business Overview
11.17.3 Sanofi Pasteur COVID-19 Inactivated Vaccine Introduction
11.17.4 Sanofi Pasteur Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.17.5 Sanofi Pasteur Recent Development
11.18 Baylor
11.18.1 Baylor Company Detail
11.18.2 Baylor Business Overview
11.18.3 Baylor COVID-19 Inactivated Vaccine Introduction
11.18.4 Baylor Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.18.5 Baylor Recent Development
11.19 iBio, Inc.
11.19.1 iBio, Inc. Company Detail
11.19.2 iBio, Inc. Business Overview
11.19.3 iBio, Inc. COVID-19 Inactivated Vaccine Introduction
11.19.4 iBio, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.19.5 iBio, Inc. Recent Development
11.20 Moderna, Inc.
11.20.1 Moderna, Inc. Company Detail
11.20.2 Moderna, Inc. Business Overview
11.20.3 Moderna, Inc. COVID-19 Inactivated Vaccine Introduction
11.20.4 Moderna, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.20.5 Moderna, Inc. Recent Development
11.21 Curevac
11.21.1 Curevac Company Detail
11.21.2 Curevac Business Overview
11.21.3 Curevac COVID-19 Inactivated Vaccine Introduction
11.21.4 Curevac Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.21.5 Curevac Recent Development
11.22 ImmunoPrecise
11.22.1 ImmunoPrecise Company Detail
11.22.2 ImmunoPrecise Business Overview
11.22.3 ImmunoPrecise COVID-19 Inactivated Vaccine Introduction
11.22.4 ImmunoPrecise Revenue in COVID-19 Inactivated Vaccine Business (2018-2023)
11.22.5 ImmunoPrecise Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global COVID-19 Inactivated Vaccine Market Size Growth Rate by Type (US$ Million): 2018 VS 2023 VS 2033
Table 2. Key Players of In Clinical Trials
Table 3. Key Players of Out-of-Clinical Trials
Table 4. Global COVID-19 Inactivated Vaccine Market Size Growth by Application (US$ Million): 2018 VS 2023 VS 2033
Table 5. Global COVID-19 Inactivated Vaccine Market Size by Region (US$ Million): 2018 VS 2023 VS 2033
Table 6. Global COVID-19 Inactivated Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global COVID-19 Inactivated Vaccine Market Share by Region (2018-2023)
Table 8. Global COVID-19 Inactivated Vaccine Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global COVID-19 Inactivated Vaccine Market Share by Region (2024-2033)
Table 10. COVID-19 Inactivated Vaccine Market Trends
Table 11. COVID-19 Inactivated Vaccine Market Drivers
Table 12. COVID-19 Inactivated Vaccine Market Challenges
Table 13. COVID-19 Inactivated Vaccine Market Restraints
Table 14. Global COVID-19 Inactivated Vaccine Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global COVID-19 Inactivated Vaccine Market Share by Players (2018-2023)
Table 16. Global Top COVID-19 Inactivated Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Inactivated Vaccine as of 2023)
Table 17. Ranking of Global Top COVID-19 Inactivated Vaccine Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by COVID-19 Inactivated Vaccine Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players COVID-19 Inactivated Vaccine Product Solution and Service
Table 21. Date of Enter into COVID-19 Inactivated Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global COVID-19 Inactivated Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global COVID-19 Inactivated Vaccine Revenue Market Share by Type (2018-2023)
Table 25. Global COVID-19 Inactivated Vaccine Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global COVID-19 Inactivated Vaccine Revenue Market Share by Type (2024-2033)
Table 27. Global COVID-19 Inactivated Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global COVID-19 Inactivated Vaccine Revenue Market Share by Application (2018-2023)
Table 29. Global COVID-19 Inactivated Vaccine Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global COVID-19 Inactivated Vaccine Revenue Market Share by Application (2024-2033)
Table 31. North America COVID-19 Inactivated Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2023 VS 2033
Table 32. North America COVID-19 Inactivated Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America COVID-19 Inactivated Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe COVID-19 Inactivated Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2023 VS 2033
Table 35. Europe COVID-19 Inactivated Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe COVID-19 Inactivated Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific COVID-19 Inactivated Vaccine Market Size Growth Rate by Region (US$ Million): 2018 VS 2023 VS 2033
Table 38. Asia-Pacific COVID-19 Inactivated Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific COVID-19 Inactivated Vaccine Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America COVID-19 Inactivated Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2023 VS 2033
Table 41. Latin America COVID-19 Inactivated Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America COVID-19 Inactivated Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa COVID-19 Inactivated Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2023 VS 2033
Table 44. Middle East & Africa COVID-19 Inactivated Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa COVID-19 Inactivated Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 46. Inovio Pharmaceuticals Company Detail
Table 47. Inovio Pharmaceuticals Business Overview
Table 48. Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Product
Table 49. Inovio Pharmaceuticals Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 50. Inovio Pharmaceuticals Recent Development
Table 51. Takis Biotech (Evvivax) Company Detail
Table 52. Takis Biotech (Evvivax) Business Overview
Table 53. Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Product
Table 54. Takis Biotech (Evvivax) Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 55. Takis Biotech (Evvivax) Recent Development
Table 56. Zydus Cadila Company Detail
Table 57. Zydus Cadila Business Overview
Table 58. Zydus Cadila COVID-19 Inactivated Vaccine Product
Table 59. Zydus Cadila Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 60. Zydus Cadila Recent Development
Table 61. Codagenix, Inc. Company Detail
Table 62. Codagenix, Inc. Business Overview
Table 63. Codagenix, Inc. COVID-19 Inactivated Vaccine Product
Table 64. Codagenix, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 65. Codagenix, Inc. Recent Development
Table 66. GeoVax, Inc. Company Detail
Table 67. GeoVax, Inc. Business Overview
Table 68. GeoVax, Inc. COVID-19 Inactivated Vaccine Product
Table 69. GeoVax, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 70. GeoVax, Inc. Recent Development
Table 71. Bravovax Company Detail
Table 72. Bravovax Business Overview
Table 73. Bravovax COVID-19 Inactivated Vaccine Product
Table 74. Bravovax Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 75. Bravovax Recent Development
Table 76. Janssen Pharmaceutical Companies Company Detail
Table 77. Janssen Pharmaceutical Companies Business Overview
Table 78. Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Product
Table 79. Janssen Pharmaceutical Companies Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 80. Janssen Pharmaceutical Companies Recent Development
Table 81. Altimmune Company Detail
Table 82. Altimmune Business Overview
Table 83. Altimmune COVID-19 Inactivated Vaccine Product
Table 84. Altimmune Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 85. Altimmune Recent Development
Table 86. Vaxart Company Detail
Table 87. Vaxart Business Overview
Table 88. Vaxart COVID-19 Inactivated Vaccine Product
Table 89. Vaxart Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 90. Vaxart Recent Development
Table 91. CanSino Biologics Company Detail
Table 92. CanSino Biologics Business Overview
Table 93. CanSino Biologics COVID-19 Inactivated Vaccine Product
Table 94. CanSino Biologics Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 95. CanSino Biologics Recent Development
Table 96. ExpreS2ion Biotechnologies ApS Company Detail
Table 97. ExpreS2ion Biotechnologies ApS Business Overview
Table 98. ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Product
Table 99. ExpreS2ion Biotechnologies ApS Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 100. ExpreS2ion Biotechnologies ApS Recent Development
Table 101. Clover Biopharmaceuticals Company Detail
Table 102. Clover Biopharmaceuticals Business Overview
Table 103. Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Product
Table 104. Clover Biopharmaceuticals Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 105. Clover Biopharmaceuticals Recent Development
Table 106. GSK Company Detail
Table 107. GSK Business Overview
Table 108. GSK COVID-19 Inactivated Vaccine Product
Table 109. GSK Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 110. GSK Recent Development
Table 111. Vaxil Bio Ltd. Company Detail
Table 112. Vaxil Bio Ltd. Business Overview
Table 113. Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Product
Table 114. Vaxil Bio Ltd. Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 115. Vaxil Bio Ltd. Recent Development
Table 116. Generex Company Detail
Table 117. Generex Business Overview
Table 118. Generex COVID-19 Inactivated Vaccine Product
Table 119. Generex Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 120. Generex Recent Development
Table 121. Novavax, Inc. Company Detail
Table 122. Novavax, Inc. Business Overview
Table 123. Novavax, Inc. COVID-19 Inactivated Vaccine Product
Table 124. Novavax, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 125. Novavax, Inc. Recent Development
Table 126. Sanofi Pasteur Company Detail
Table 127. Sanofi Pasteur Business Overview
Table 128. Sanofi Pasteur COVID-19 Inactivated Vaccine Product
Table 129. Sanofi Pasteur Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 130. Sanofi Pasteur Recent Development
Table 131. Baylor Company Detail
Table 132. Baylor Business Overview
Table 133. Baylor COVID-19 Inactivated Vaccine Product
Table 134. Baylor Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 135. Baylor Recent Development
Table 136. iBio, Inc. Company Detail
Table 137. iBio, Inc. Business Overview
Table 138. iBio, Inc. COVID-19 Inactivated Vaccine Product
Table 139. iBio, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 140. iBio, Inc. Recent Development
Table 141. Moderna, Inc. Company Detail
Table 142. Moderna, Inc. Business Overview
Table 143. Moderna, Inc. COVID-19 Inactivated Vaccine Product
Table 144. Moderna, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 145. Moderna, Inc. Recent Development
Table 146. Curevac Company Detail
Table 147. Curevac Business Overview
Table 148. Curevac COVID-19 Inactivated Vaccine Product
Table 149. Curevac Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 150. Curevac Recent Development
Table 151. ImmunoPrecise Company Detail
Table 152. ImmunoPrecise Business Overview
Table 153. ImmunoPrecise COVID-19 Inactivated Vaccine Product
Table 154. ImmunoPrecise Revenue in COVID-19 Inactivated Vaccine Business (2018-2023) & (US$ Million)
Table 155. ImmunoPrecise Recent Development
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Global COVID-19 Inactivated Vaccine Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global COVID-19 Inactivated Vaccine Market Share by Type: 2023 VS 2033
Figure 3. In Clinical Trials Features
Figure 4. Out-of-Clinical Trials Features
Figure 5. Global COVID-19 Inactivated Vaccine Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global COVID-19 Inactivated Vaccine Market Share by Application: 2023 VS 2033
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Other Case Studies
Figure 10. COVID-19 Inactivated Vaccine Report Years Considered
Figure 11. Global COVID-19 Inactivated Vaccine Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global COVID-19 Inactivated Vaccine Market Size, (US$ Million), 2018 VS 2023 VS 2033
Figure 13. Global COVID-19 Inactivated Vaccine Market Share by Region: 2023 VS 2033
Figure 14. Global COVID-19 Inactivated Vaccine Market Share by Players in 2023
Figure 15. Global Top COVID-19 Inactivated Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Inactivated Vaccine as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by COVID-19 Inactivated Vaccine Revenue in 2023
Figure 17. North America COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America COVID-19 Inactivated Vaccine Market Share by Country (2018-2033)
Figure 19. United States COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Canada COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe COVID-19 Inactivated Vaccine Market Share by Country (2018-2033)
Figure 23. Germany COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. France COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. U.K. COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Italy COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Russia COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Nordic Countries COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific COVID-19 Inactivated Vaccine Market Share by Region (2018-2033)
Figure 31. China COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Japan COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. South Korea COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Southeast Asia COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. India COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Australia COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America COVID-19 Inactivated Vaccine Market Share by Country (2018-2033)
Figure 39. Mexico COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Brazil COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa COVID-19 Inactivated Vaccine Market Share by Country (2018-2033)
Figure 43. Turkey COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Saudi Arabia COVID-19 Inactivated Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Inovio Pharmaceuticals Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 46. Takis Biotech (Evvivax) Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 47. Zydus Cadila Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 48. Codagenix, Inc. Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 49. GeoVax, Inc. Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 50. Bravovax Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 51. Janssen Pharmaceutical Companies Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 52. Altimmune Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 53. Vaxart Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 54. CanSino Biologics Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 55. ExpreS2ion Biotechnologies ApS Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 56. Clover Biopharmaceuticals Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 57. GSK Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 58. Vaxil Bio Ltd. Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 59. Generex Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 60. Novavax, Inc. Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 61. Sanofi Pasteur Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 62. Baylor Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 63. iBio, Inc. Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 64. Moderna, Inc. Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 65. Curevac Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 66. ImmunoPrecise Revenue Growth Rate in COVID-19 Inactivated Vaccine Business (2018-2023)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed